



CULTIVATING INNOVATION: GOOGLE, GINGKO BIOWORKS, & AI

Ginkgo Bioworks, a company specializing in cutting-edge cell programming and biosecurity solutions, has teamed up with Google Cloud to establish a robust five-year collaborative cloud and Artificial Intelligence partnership. The objective is to empower Ginkgo in the development and implementation of AI tools tailored for the realms of biology and biosecurity. Within this strategic collaboration, Ginkgo will focus on creating advanced large language models (LLMs) on Google Cloud's Vertex AI platform, concentrating on diverse fields such as genomics, protein function, and synthetic biology. This initiative is set to expedite innovation and breakthroughs for Ginkgo's clients across various sectors like pharmaceutical research, agriculture, industrial manufacturing, and biosecurity. Continue reading [here](#).

TABLE OF CONTENTS

Save the Date: GMDP Academy 2023 Graduation Ceremony • P. 2

Conversations with the Academy: The Growing Relevance of RWE Studies • P. 3

The Global Fight against Meningitis • P. 4

2024 applications for CMD program now open • P. 4

Harvard medical school study reveals nf-y of PAX3-FOXO1 in rhabdomyosarcoma • P. 5

Curious2024-Future Insight conference • P. 5

Graduation Ceremony

2023 Cohort



We are thrilled to announce the inaugural Graduation Ceremony of the GMDP Academy, celebrating the remarkable achievements of our students who have successfully completed the Certification in Medicines Development program this academic year.

Save the Date:

Date & Time: 10AM – 11:15AM EST, Tuesday, January 30, 2024

Location: Virtual via Zoom

[Click here to register](#)

This pivotal event signifies not just the conclusion of a demanding academic journey but also the continuance of promising careers in the field of medicines development.

The ceremony agenda will feature:

- An enlightening keynote address
- Recognition of our graduates
- Insights from program participants
- Acknowledgements to our esteemed sponsors
- Thought-provoking closing remarks.

The palpable enthusiasm from our academic staff and the graduates guarantees an event brimming with gratitude, introspection, and hopeful anticipation.

We kindly encourage sharing this invitation with colleagues and anyone invested in the future of medicines development. This ceremony is an opportunity for our entire community to come together in celebration of our collective accomplishments.

Please mark your calendars, register using the provided link, amplify the message on platforms like LinkedIn, and watch out for further updates.



Conversations with the Academy

Presents:

"The Growing Relevance of RWE Studies"

October 30, 2023
9:00AM to 10:00AM EST



Laura Fabbri, PhD
Head of Real World Evidence
Chiesi Pharmaceutical
Parma, Italy



Sreeram Ramagopalan, PhD, MBA
Principal and Market Access
and Payer Evidence Lead
Lane Clark & Peacock
London, England

1

Real World Evidence (RWE) studies are gaining more clinical importance, as pharma companies, Investigators and Regulatory agencies seek improved knowledge of the benefit/risk ratio of a new medicine when it is used in normal conditions. Indeed, regulators are so interested in them, that they are pleased to see them as part of the NDA dossier. This captivating webinar with Laura Fabbri, PhD and Sreeram Ramagopalan, PhD, MBA, explores the evolving landscape of RWE and highlights its pivotal role in drug development.

Learning Objectives

- 1. Understand the clinical and regulatory importance of RWE studies.**
- 2. Appreciate how RWE studies can also be useful in the HTA preparation.**
- 3. Comment on the real approach a company is planning in implementing these studies.**

[Register Now](#)

PROGRESS AND CHALLENGES IN THE GLOBAL FIGHT AGAINST MENINGITIS: A COMPREHENSIVE ANALYSIS

Despite being largely preventable, meningitis still results in a significant number of global fatalities each year. The World Health Organization (WHO) has established ambitious targets to decrease the prevalence of meningitis cases by 2030. Evaluating the patterns in the worldwide burden of meningitis can facilitate the monitoring of progress and identification of gaps in achieving these objectives.

Utilizing data from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019, the research aimed to evaluate new cases and fatalities linked to acute infectious meningitis based on the cause and age from 1990 to 2019, covering 204 countries and territories.



To estimate meningitis-related mortality, the authors employed vital registration, verbal autopsy, sample-based vital registration, and mortality surveillance data.

Continue reading [here](#).

CATAPULT YOUR MEDICINES DEVELOPMENT CAREER: SUBMIT YOUR APPLICATION NOW

The GMDP Academy, in collaboration with King's College London, is pleased to accept applications for the 2024 cohort of the highly acclaimed Certification in Medicines Development (CMD) program.

Don't miss your chance to become part of a truly unique educational journey in Medicines Development! Join fellow professionals from around the world and advance your career with the 2024 GMDP Academy-King's College London Certification in Medicines Development Program .


Group rates are available for sponsoring organizations. For more information contact admissions@gmdpacademy.org.

[Apply Today](#)

HARVARD MEDICAL SCHOOL STUDY REVEALS NF-Y OF PAX3-FOXO1 IN RHABDOMYOSARCOMA

Rhabdomyosarcoma, a fatal cancer in children, requires innovative treatments. This recent study introduces an effective genetic screening method aimed at identifying genes that promote the transition of rhabdomyosarcoma cells into normal muscle cells. The method facilitated the discovery of NF-Y, a significant protein influencing the behavior of rhabdomyosarcoma.

Through the application of CRISPR-based genetic manipulation, the researchers achieved the conversion of rhabdomyosarcoma cells into differentiated muscle cells, elucidating the underlying mechanism. Due to the prevalence of cell differentiation deficiencies in various human sarcomas, this approach might have broad applicability in the investigation of these tumors.



Moreover, the findings suggest NF-Y as a prospective target for the development of differentiation therapy for rhabdomyosarcoma. Continue reading [here](#).

ANNOUNCING THE CURIOUS2024-FUTURE INSIGHT CONFERENCE IN MAINZ, GERMANY



Stay up to date on upcoming events in the scientific community. Check out this amazing conference!

From the Curious2024-Future Insight website:

Science has always been the engine that powered human progress. Each new generation across the millennia has harnessed their curiosity to discover new solutions to redefine their tomorrow. But what will our tomorrow look like? And what role will you play to ensure our future is a bright one? Where everyone everywhere can live healthier, and more sustainably. Where science is embraced as a powerful force for good.

July 10-11, 2024 in Mainz, Germany. Click [here](#) to learn more.

REFERENCES

1. <https://www.prnewswire.com/news-releases/ginkgo-bioworks-and-google-cloud-partner-to-build-next-generation-ai-platform-for-biological-engineering-and-biosecurity-301912283.html>
2. Wunrow, H. Y., Bender, R. G., Vongpradith, A., Sirota, S. B., Swetschinski, L. R., Novotney, A., Gray, A. P., Ikuta, K. S., Sharara, F., Wool, E., Aali, A., Abd-El salam, S., Abdollahi, A., Aziz, J. M. A., Abidi, H., Aboagye, R. G., Abolhassani, H., Abu-Gharbieh, E., Adamu, L. H., . . . Kyu, H. H. (2023). Global, regional, and national burden of meningitis and its aetiologies, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet Neurology*, 22(8), 685–711. [https://doi.org/10.1016/s1474-4422\(23\)00195-3](https://doi.org/10.1016/s1474-4422(23)00195-3)
3. Sroka, M. W., Skopelitis, D. S., Vermunt, M. W., Preall, J., Demerdash, O. E., De Almeida, L. M. N., Chang, K., Utama, R., Gryder, B. E., Caligiuri, G., Ren, D., Nalbant, B., Milazzo, J. P., Tuveson, D. A., Dobin, A., Hiebert, S. W., Stengel, K. R., Mantovani, R., Khan, J., . . . Vakoc, C. R. (2023). Myo-differentiation reporter screen reveals NF-Y as an activator of PAX3–FOXO1 in rhabdomyosarcoma. *Proceedings of the National Academy of Sciences of the United States of America*, 120(36). <https://doi.org/10.1073/pnas.2303859120>

Thanks for reading!

The GMDP Academy Newsletter is published twice monthly and is compiled by the following:

Medical Editor: Domenico Criscuolo

Media Manager: Whitney English

Editorial Board: Pravin Chopra, Jacob Coats, Honorio Silva, Peter Stonier

Operations Office: Amanda Schmitt, Gustavo Silva, Kit Vale

CONTACT US:



420 Lexington Ave. Ste. 300
New York, NY 10170

(332) 333-2438